#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Bronchiolitis Barth syndrome Infertility female Deafness neurosensory Ewing's sarcoma Malignant oligodendroglioma Hereditary optic atrophy Palmar-plantar erythrodysaesthesia syndrome Vascular calcification Autoimmune hepatitis Cutaneous T-cell lymphoma stage I Ehlers-Danlos syndrome Splenic marginal zone lymphoma Paraneoplastic neurological syndrome Systemic scleroderma More trials…

    Learn about Rare Diseases

    MELAS syndrome – Basic Information Mantle cell lymphoma refractory – Diagnostics Skin angiosarcoma – Diagnostics Mantle cell lymphoma – Treatment Biotinidase deficiency – Treatment Nephroblastoma – Trials in Disease Inclusion body myositis – Basic Information Familial haemophagocytic lymphohistiocytosis – Basic Information Hepatic angiosarcoma Biotinidase deficiency – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Imidapril Hydrochloride Tianeptine Ep0042 Levocetirizine Dihydrochloride Dazodalibep Daridorexant Regn7075 Litenimod Sodium Eftilagimod Alfa Mitazalimab Citric Acid Monohydrate Bio89-100 Human Plasma Protein RNMB3 Tremelimumab Upadacitinib Milrinone Candesartan Cilexetil Dupilumab SULBACTAM SODIUM More therapies…

    Learn about Your Condition

    Respiratory distress Gastrectomy Peripheral artery stenosis Pulmonary resection T-cell type acute leukaemia Infantile apnoea Colon cancer metastatic Metabolic syndrome Glucose tolerance impaired Essential hypertension Osteoporosis postmenopausal Deafness traumatic Lung adenocarcinoma stage IV Hydrocephalus Carcinoid tumour pulmonary More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Graft versus host disease

  • Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

    Not recruiting

    3 1
    Investigated Diseases:
    • Allogenic stem cell transplantation
    • Graft versus host disease
    Investigated Drugs:
    • Itolizumab
    Belgium France Germany Italy Portugal Spain

  • Comparison of Post-Transplant Cyclophosphamide versus Anti-T Lymphocyte Immunoglobulin for Prevention of Graft versus Host Disease in Patients Receiving Unrelated Donor Transplantation

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute graft versus host disease
    • Graft versus host disease
    Investigated Drugs:
    • Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit
    • Tacrolimus
    • Cyclophosphamide
    Germany

  • Study on the Safety of Decidua Stromal Cells for Patients with Steroid-Resistant Severe Acute Graft vs Host Disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Graft versus host disease
    Investigated Drugs:
    • Allogeneic Placenta-Derived Decidual Stromal Cells, Ex-Vivo Expanded
    Denmark Norway Sweden

  • Study on the Safety and Effectiveness of Human Alpha1-Proteinase Inhibitor for Preventing Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplant.

    Not recruiting

    4 1 1
    Investigated Diseases:
    • Graft versus host disease
    Investigated Drugs:
    • Human Alpha1-Proteinase Inhibitor
    Germany Italy Spain
Previous Page
1 2

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!